Mean Central Foveal Thickness Research Articles

Surgical outcomes in patients with lamellar macular holes selected based on the optical coherence tomography consensus definition

PurposeThe surgical indication for lamellar macular holes (LMH) is controversial due to a misclassification of different macular diseases. A consensus based on an optical coherence tomography (OCT) definition has recently been suggested. The aim of this study was to investigate the surgical outcomes of patients with LMH selected based on this OCT-based consensus definition.MethodsRetrospective review of patients who underwent surgery for LMH with a follow-up of at least 3 months. Anatomical OCT criteria for the diagnosis of LMH were the presence of an irregular foveal contour with foveal cavitation and a loss of retinal tissue. Cases of macular pseudoholes and epiretinal membrane foveoschisis were excluded. Surgery consisted in pars plana vitrectomy with centripetal peri-hole peeling of epiretinal proliferation and internal limiting membrane. Pre- and postoperative visual acuities (VA) were compared, and changes in OCT anatomical features, including the restoration of the foveal profile and outer retinal layers, were assessed.ResultsEleven eyes of 11 patients were included, of which 9 eyes (81.8%) showed proliferation on preoperative OCT. The mean VA improved from 0.44 ± 0.19 LogMAR (20/55 Snellen equivalent) to 0.16 ± 0.08 LogMAR (20/28 Snellen equivalent), after a mean follow-up of 7.2 ± 2.9 months (P = 0.02). Postoperatively, all eyes showed a restored foveal profile. The mean central foveal thickness increased from 127.6 ± 29.9 μm to 209.0 ± 44.0 μm (P = 0.001). At baseline, ellipsoid zone disruption and external limiting membrane disruption were found in 9 and 7 eyes, respectively. Postoperatively, the ellipsoid zone and external limiting membrane were restored in respectively 6/9 eyes (66.7%) and 5/7 eyes (71.4%). No cases of postoperative full-thickness macular hole were found.ConclusionIn patients with LMH carefully selected based on the recent OCT-based criteria and showing a loss of retinal tissue, the foveal architecture was restored and the VA was improved after vitrectomy with peri-hole peeling for epiretinal proliferation.

COMPARISON OF INTRAVITREAL BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE WITH INTRAVITREAL BEVACIZUMAB ALONE IN MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION

OBJECTIVES: To compare the effect of intravitreal-bevacizumab (IVB) and intravitreal-triamcinolone (IVT) with IVB alone on visual acuity (VA) and central foveal thickness (CFT) in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). METHODS: This quasi-experimental study was conducted from June 2018 to December 2018 on patients with ME secondary to CRVO, admitted at Hayatabad Medical Complex, Peshawar, Pakistan. Out of thirty patients included in this study, fifteen were included in Group-A (received combination therapy IVT and IVB) and 15 in Group-B (received IVB alone). The subjects were followed up at 3rd and 6th month post-treatment and changes in VA (logMAR) and CFT were recorded at each visit. The comparative analyses of variables were carried out with-in the groups and between the groups. RESULTS: Mean age of patients was 60.93±4.38 years (group-A) and 60.73±3.67 years (group-B). Mean VA at baseline & 6th month was 0.87±0.09 & 0.32±0.06 in group-A as compared to 0.88±0.10 to 0.44±0.06 LogMAR units in group-B respectively (p<0.001). Mean CFT at baseline & 6th month was 673.67±38.33 & 264.4±16.73 in group-A as compared to 674.07±36.32 & 271.01±20.14 μm in group-B respectively (p<0.001). There was no significant difference in CFT between the two groups at 3rd month (p=0.84) and 6th month (p<0.33) post-treatment, although it was statistically significant when compared within the groups.  CONCLUSION: Combined treatment is more effective than IVB alone in improving VA in CRVO related ME. However, the effect of combined treatment on CVT is not superior to IVB alone.

Management of macular edema secondary to branch retinal vein occlusion-combined treatment with intravitreal bevacizumab and ozurdex implant

To evaluate the efficacy and safety of a dexamethasone implant in combination with intravitreal bevacizumab injection in the management of macular edema secondary to branch retinal venous occlusion. 10 eyes were prospectively investigated. Each eye was treated with intravitreal bevacizumab followed by intravitreal ozurdex at a two-week interval. Recurrence of macular edema was treated with ozurdex only. Patient were evaluated preoperatively with BCVA, IOP, OCT and fundus evaluation and followed up at 15 days, 2months and 4months of ozurdex injection. Fallow up all patient for 1 year duration. Mean BCVA at presentation was 0.81 log mar, and that improved to after 15 days of intravitreal bevacizumab was 0.55 log mar. At 15 days, 2 months and 4 months of intravitreal ozurdex implantation mean BCVA was 0.54logmar, 0.54 log mar and 0.6logmar respectively. Mean central foveal retinal thickness at presentation was 538 µm and reduced to 235 µm, after intravitreal bevacizumab. At 15 days, 2 months and 4 months after intravitreal ozurdex implantation mean central foveal retinal thickness was 182.14 µm, 189.28 µm and 352.14 µm respectively. Mean Intraocular pressure (IOP) was elevated about 1 mm of Hg after bevacizumab, about 3 mm of Hg after 4 months of ozurdex with using single anti glaucoma medication and one patient had progression of cataract after 2 injection of ozurdex. Combined treatment of intravitreal bevacizumab and ozurdex shows better and a sustained functional outcome. Increased intraocular pressure and cataract formation can be potential concerns and should be monitored.

Transient accumulation of subretinal fluid after half-fluence photodynamic therapy in neovascular age-related macular degeneration

BackgroundPhotodynamic therapy (PDT) is known to occlude choroidal neovascularisation selectively, and there have been several reports on its adverse effects on the normal choroid and retinal pigment epithelium, resulting in decreased vision.MethodsThis retrospective interventional case series aimed to investigate the changes in visual acuity and retinal thickness in the immediate post-treatment period after half-fluence PDT, administered alone or with anti-vascular endothelial growth factor and steroids, in 29 eyes (26 patients) with neovascular age-related macular degeneration. The patients’ best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography images were measured 1 day, 1 week, and 1 month post-treatment.ResultsCompared to the pre-treatment CFT (270.38 μm), the mean CFT was significantly increased 1 day post-treatment (387.07 μm, P = 0.001), which then started to decrease, with a mean CFT of 269.32 μm (P = 0.516) at 1 week, and of 240.66 μm (P = 0.066) at 1 month post-treatment. All CFT increases were due to the accumulation of subretinal fluid (SRF), rather than the intraretinal or subretinal pigment epithelium fluid. Relative to the pre-treatment BCVA (0.59 logMAR), the mean BCVA at 1 day (0.74 logMAR, P = 0.005) and 1 week (0.75 logMAR, P = 0.002) post-treatment was significantly deteriorated; however, it recovered to 0.62 logMAR at 1 month. The patterns of change in CFT and BCVA did not differ according to treatment modality.ConclusionsHalf-fluence PDT resulted in accumulation of SRF in the immediate post-treatment period; this damage mostly recovered within a week, and the BCVA was restored within a month.

Macular pigment optical density after panretinal photocoagulation

ABSTRACT Clinical relevance Panretinal photocoagulation, an important treatment method in diabetic retinopathy, can affect macular pigment optical density, which has protective and antioxidant properties. As a result of this effect, the retina may become more sensitive to high‐energy visible light. Background The current study assesses the effect of panretinal photocoagulation treatment on macular pigment optical density, which has essential functions for the retina. Methods In this prospective clinical study, the colour perimetry method was used to measure macular pigment optical density. Thirty‐six eyes of 36 participants with severe non‐proliferative diabetic retinopathy without macular involvement were included in the study. Conventional panretinal photocoagulation treatments were applied at baseline, one month, two months, and at three months to the participants who clinically required this treatment. Macular pigment optical density and retinal thickness measurements were performed at baseline, months one, two, three and six. Results The mean macular pigment optical density reduction in the fovea over the six-months was 0.02 ± 0.02 logarithmic units (p < 0.001). Similarly, the pericentral areas declined by 0.04 ± 0.03 logarithmic units (p < 0.001). Mean central macular thickness and foveal thickness increased by 5.03 ± 5.02 μm and 2.78 (interquartile range 2–4) μm, respectively. In this study, correlation analysis shows that the laser energy applied was significantly and strongly correlated with reductions in macular pigment optical density (for the fovea and pericentral area respectively: r = −0.855, p < 0.001; r = −0.895, p < 0.001). Further, there were significant and strong correlations between the applied laser energy, and central macular thickness and fovea thickness (r = 0.751, p < 0.001; ρ = 0.718, p < 0.001, respectively). Conclusion Panretinal photocoagulation may potentially cause a decrease in macular pigment density in proportion to the laser energy applied.

Characterization of Retinal Thickness in Individuals with Albinism: Baseline Data for a Black South African Population.

IntroductionThe central retina is responsible for several visual functions and continues to develop postnatally. In albinism, which is a genetic disorder characterized by impaired melanin biosynthesis, the development of the central retina is prematurely arrested and results in foveal hypoplasia. Retinal thickness measurements can be determined non-invasively using optical coherence tomography systems. This article reports on the retinal thickness measurements of individuals with albinism in South Africa to aid in the assessment and management of affected individuals.MethodsThe study used a comparative research design and included 60 individuals (30 albinism and 30 controls) aged from 10 to 30 years who accessed the eye clinic at a tertiary institution in KwaZulu-Natal, South Africa. The Optovue iVue100 optical coherence tomographer was used to measure retinal thickness in the nine Early Treatment Diabetic Retinopathy Study (ETDRS) sectors including the central foveal, parafoveal and perifoveal regions. Study data were analysed using descriptive and inferential statistics.ResultsThe mean central foveal thickness was significantly higher in individuals with albinism compared with controls (289 µm versus 239 µm, p < 0.001). In contrast, control participants showed thicker retinal thickness measurements in the other ETDRS sectors (p < 0.001). The nasal and temporal quadrants were thickest and thinnest, respectively, in the parafoveal and perifoveal regions for the albinism and control groups.ConclusionIndividuals with albinism, aged from 10 to 30 years, have higher central foveal thickness but thinner retinal thickness measurements in the parafoveal and perifoveal regions. Optometric personnel should consider these measurements when assessing individuals with albinism with foveal retinal diseases.

Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab.

Purpose:The aim of this study was to evaluate the efficacy and safety of Razumab (the biosimilar Ranibizumab by Intas Pharmaceuticals Ltd.) for the treatment of chorioretinal vascular diseases such as diabetic macular edema (DME), choroidal neovascular membrane (CNVM), and macular edema secondary to retinal vein occlusion (RVO).Methods:We conducted a single-center, retrospective study, including patients with DME, CNVM, and RVO, who had received treatment with Razumab® between October 2018 and September 2019. Primary outcome measures were the changes in corrected distance visual acuity (CDVA) and central foveal thickness (CFT) from baseline to 1 month and 3 months. Secondary outcome measures included intraocular pressure (IOP) at day 1, any signs of ocular inflammation or systemic adverse events during the follow-up.Results:One hundred and fifty-three eyes of 141 patients were analyzed. The indications included DME in 70 (45.8%) eyes, CNVM in 70 (45.8%) eyes, and RVO in 13 (8.4%) eyes. Mean CDVA improved from baseline (0.62 ± 0.44) to month 1 (0.45 ± 0.42) and maintained till 3 months (0.42 ± 0.44; P < 0.001). Mean CFT showed significant reduction from baseline (405.68 ± 192.422 μm) to month 1 (286.08 ± 118.36 μm) and month 3 (271 ± 104.24 μm; P < 0.001). None of the eyes recorded IOP >20 mmHg on day 1. No evidence of ocular toxicity or systemic adverse event was noted.Conclusion:Razumab® showed a rapid improvement in CDVA and CFT in most of the eyes with efficacy observed as early as 1 month and maintained till 3 months. The biosimilar Ranibizumab can be a safe and effective low-cost drug for treating macular diseases.

Therapeutic effects of pars plana vitrectomy combined with internal limiting membrane peeling on high myopic foveoschisis

Objective: To observe the clinical efficacy of vitrectomy combined with foveal-sparing circular internal limiting membrane peeling with the central fovea reserved in patients with high myopic foveoschisis. Methods: Case-control study. A total of 72 patients (86 eyes) with foveoschisis due to high myopia who underwent vitrectomy combined with internal limiting membrane peeling in Lishui Municipal Central Hospital of Zhejiang Province from June 2016 to May 2017 were enrolled, including 18 males (18 eyes) and 54 females (68 eyes), aged (50.5±8.9) years. The patients were randomly divided into the observation group (34 cases, 43 eyes) and the control group (38 cases, 43 eyes) using a random number table and random number residual grouping method. Vitrectomy was performed in all patients. In the control group, the limiting membrane in the macular area was removed during surgery. In the observation group, the foveal annular internal limiting membrane was preserved during surgery. In severe cases, cataract extraction was performed. Results: In the observation group, the mean central foveal thickness (CFT) on optical coherence tomography was (723.49±130.95) μm preoperatively and decreased to (286.33±210.73) μm postoperatively, and the difference had statistical significance (t=17.059, P=0.000). In 39 eyes with complete or partial healing of the foveal split, the best corrected visual acuity (BCVA) was (0.99±0.40) logMAR before the treatment and increased to 0.68±0.24 after the treatment, and the difference had statistical significance (t=7.585, P=0.000). In the control group, the mean CFT was (726.98±140.62) μm and (297.88±241.56.) μm before and after the treatment, respectively, and the difference had statistical significance (t=16.271, P=0.000). In 38 eyes with complete or partial healing of the foveal split, the BCVA increased from preoperative 1.04±0.47 to postoperative 0.69±0.21, and the difference had statistical significance (t=6.707, P=0.00). With the follow-up time as the efficacy determination time, there was no significant difference in BCVA (t=0.22, P=0.983) and CFT (t=0.236, P=0.814) between the observation group and the control group (P>0.05); there was significant difference in the incidence rate of macular holes (P=0.026). There was no statistically significant difference in the rate of complete macular morphology healing between the two groups (P=0.816). Conclusion: Vitrectomy combined with foveal-sparing circular internal limiting membrane peeling can effectively treat high myopic macular holes and reduce the formation of postoperative macular holes. (Chin J Ophthalmol, 2020, 56: 928-932).

Assessment of Macular Function Following Internal Limiting Membrane Peeling With ILM Blue®.

PurposeTo evaluate clinical outcome after surgery of idiopathic epiretinal membranes (ERM) with internal limiting membrane (ILM) peeling using a commercial combination of Brilliant blue G (BBG, 0.25 mg/ml) with 4% polyethylene glycol (PEG).MethodsIt was a prospective, single-center study. Macular surgery was performed due to ERM (n = 18) by two experienced surgeons. Exclusion criteria were secondary ERM, previous retinal surgery and pharmacological treatment. Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and multifocal ERG (RETIscan) were assessed at baseline and three months after surgery.ResultsThe BCVA improved from baseline 0.4 ± 0.13 logMAR to 0.3 ± 0.2 logMAR after three months (p > 0.05). The mean central foveal thickness was reduced from 407 ± 85 μm to 366 ± 56 μm after three months (p > 0.05). At baseline, the mean P1 amplitude (nV/deg2) was 53.5 ± 32.1 in ring 1 and 35.9 ± 20.1 in ring 2. Three months after surgery the mean P1 amplitude was comparable with 57.2 ± 16.3 in ring 1 and 38.0 ± 11.7 in ring 2 compared with the initial situation (p = 0.22 and p = 0.3, respectively).ConclusionBBG with 4% PEG can be used for ILM peeling in patients with idiopathic epiretinal membranes without any sign of short-term toxicity.

Secondary epiretinal membrane after Ex-Press glaucoma filtration device implant

PurposeTo estimate the frequency of epiretinal membrane (ERM) in eyes with primary open-angle glaucoma (POAG) treated with Ex-Press shunt implant. Secondarily, we aimed to assess the role of concomitant cataract surgery and the impact of the ERM on central foveal thickness and macular volume.MethodsIn this prospective, consecutive, case-control study, we enrolled 54 patients affected by PAOG and scheduled for Ex-Press device implant with or without contemporary phacoemulsification. Contralateral eyes affected by POAG and receiving anti-glaucomatous eyedrops constituted the control group. Complete ophthalmologic evaluation and spectral-domain optical coherence tomography (OCT) were performed before and 1, 3 and 6 months after surgery.ResultsTwenty-six eyes received the Ex-Press implant alone, and 28 eyes underwent the combined procedure. Six months postoperatively, we observed 18 (33%) cases of ERM: 15 (28%) of cellophane macular reflex (CMR) and 3 (6%) of pre-macular fibrosis (PMF). In the control group, 9 (17%) eyes developed an ERM: 8 (15%) were CMR, and 1 (2%) was PMF. The frequency of ERM statistically differs between treated and contralateral eyes (P = 0.032, χ2 test). The ERM frequency did not statically differ between eyes subjected to simple or combined surgery (P = 0.846, χ2 test). Mean central foveal thickness and mean macular volume did not significantly differ between groups.ConclusionThe Ex-Press glaucoma shunt may increase the risk of ERM onset regardless of the concomitant cataract surgery; however, most cases were cellophane macular reflex with limited functional and anatomical impact.

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

To evaluate choroid thickness and macular retinal metrics in treatment naive retinal vein occlusion (RVO) patients with serous retinal detachment (SRD) before and after intravitreal anti-vascular endothelial cell growth factor (VEGF) injection and to elucidate the possible role of choroid in the development of SRD and the potential role of SRD as a prognostic parameter. This is a retrospective study involving 85 RVO patients, 41 central retinal vein occlusion (CRVO), and 44 branch retinal vein occlusion (BRVO), with macular edema: 21 central retinal vein occlusion and 22 branch retinal vein occlusion with SRD and the rest without SRD. Patients were evaluated with ophthalmic examinations and swept-source optical coherence tomography (SS-OCT) both before and 4–6 weeks after intravitreal anti-VEGF treatment. Choroid thickness and retinal metrics were measured and compared between SRD and non-SRD groups within each RVO subtype. In both CRVO and BRVO patients, the mean central subfield foveal thickness (CSFT) and central subfoveal choroid thickness (CSCT) of the SRD groups were thicker than those in the non-SRD groups (p < 0.05) at onset. After one anti-VEGF injection, CSFT and FNRT decreased in all groups (p < 0.05). The CSCTs were thicker in the SRD groups compared with the non-SRD groups (p < 0.05). The mean changes of CSFT were more remarkable in the SRD groups (p < 0.05). Thicker choroid was a feature of naive RVO patients with SRD and SRD may be an indicator of better anatomical recovery of retina in RVO patients after a single dose of anti-VEGF treatment.

End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

To report the end-of-study results from the Ladder clinical trial of the Port Delivery System with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration (nAMD). Multicenter, randomized, active treatment-controlled phase 2 clinical trial. Patients diagnosed with nAMD with a documented response to anti-vascular endothelial growth factor treatment who received study treatment (N= 220). Patients were randomized 3:3:3:2 to treatment with the PDS filled with ranibizumab 10-mg/ml, 40-mg/ml, and 100-mg/ml formulations or monthly intravitreal ranibizumab 0.5-mg injections. End-of-study results for the time to first meeting refill criteria (first refill), mean change from baseline for best-corrected visual acuity (BCVA) and central foveal thickness (CFT), and safety. At study end, the mean time on study was 22.1 months (range, 10.8-37.6 months) for all PDS patients. Median time to first refill was 8.7 months, 13.0 months, and 15.8 months, and 28.9%, 56.0%, and 59.4% of patients went 12 months or longer without meeting refill criteria in the PDS 10-mg/ml, 40-mg/ml, and 100-mg/ml treatment arms, respectively. At month 22, the observed mean BCVA change from baseline was ‒4.6 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, ‒2.3 ETDRS letters,+2.9 ETDRS letters, and+2.7 ETDRS letters in the PDS 10-mg/ml, 40-mg/ml, 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg treatment arms, respectively. At month 22, the observed mean CFT change from baseline was similar in the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg treatment arms. No new safety signals were detected during the additional follow-up. Over a mean of 22 months on study, vision and anatomic outcomes were comparable between the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg arms, with a lower total number of ranibizumab treatments with the PDS. The Ladder end-of-study findings were consistent with the primary analysis, and the PDS generally was well tolerated throughout the entire study period. The PDS has the potential to reduce treatment burden in patients with nAMD while maintaining vision.

Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration.

To investigate the 4-year outcome of aflibercept treatment using a treat-and-extend (TAE) regimen for recurrent neovascular age-related macular degeneration (AMD). Retrospective observational study. Data of eyes with recurrent AMD previously treated with anti-vascular endothelial growth factor agents or photodynamic therapy and had started aflibercept treatment using a TAE regimen for the first time were collected. Best-corrected visual acuity (BCVA), intervals of treatments, the presence of exudation, central foveal thickness (CFT), and central choroidal thickness (CCT) were analyzed. Of 47 consecutive eyes, 30 of the 47 eyes completed a 4-year follow-up. The mean BCVA (logMAR) was sustained over the 4years (0.37 at baseline, 0.36 at 1year, 0.36 at 2years, 0.41 at 3years, and 0.43 at 4years, P = 0.21). Of the 30 eyes that completed the follow-up, BCVA of two eyes deteriorated by 0.3 logMAR or more at 4years. At 4years, 67% of eyes had extended treatment intervals to > 8weeks, and 47% of eyes had extended intervals to > 12weeks. Exudative changes in the macula, seen in all eyes at baseline, were only seen in 50% of the eyes at 4years. The mean CFT and CCT decreased significantly at 4years from 332μm to 248μm and from 218μm to 183μm, respectively. In clinical settings, aflibercept treatment using a TAE regimen may successfully maintain visual acuity for up to 4years even in recurrent cases of AMD.

Persistent subretinal fluid following diabetic tractional retinal detachment repair: risk factors, natural history, and management outcomes.

To study the natural history, anatomical and functional outcomes of persistent subretinal fluid (SRF) after pars plana vitrectomy (PPV) for diabetic tractional retinal detachment (TRD) and combined traction-rhegmatogenous retinal detachment (TRRD). Retrospective interventional case series of 43 patients (46 eyes) with persistent SRF following PPV for diabetic TRD or combined TRRD from January 2010 to December 2017 at single tertiary institution. Primary outcomes included best corrected visual acuity (BCVA) and central foveal thickness (CFT). Thirty-one eyes (67.4%) had macula-off TRD, 5 (10.9%) had fovea-threatening TRD and 10 (21.7%) had combined TRRD. The mean (± SD) duration of decreased vision was 48.0 ± 58.2weeks. The mean follow-up duration was 21 ± 13.2months. Residual macular SRF was detected by optical coherence tomography in all eyes at 3months and in 10 eyes (23.8%) at 12months after surgery. Only 3 eyes (6.5%) had persistent SRF at final follow up. The mean time to resolution was 10.6 ± 4.1months [range 6.0-23.0]. Thirteen eyes received additional intervention to address SRF. The mean CFT gradually improved until final follow-up (P-value < 0.001). The mean BCVA improved from 1.62 ± 0.88 LogMAR at presentation to 1.05 ± 0.76 LogMAR at final follow up. No statistically significant difference in final BCVA was found between eyes that had intervention and eyes that were observed (P value = 0.762). Persistent SRF after diabetic vitrectomy resolves slowly over time with gradual improvement in visual acuity. Additional drainage of persistent SRF may not be necessary.

One-year results of anti-vascular endothelial growth factor therapy combined with triamcinolone acetonide for macular edema associated with branch retinal vein occlusion.

To compare anti-vascular endothelial growth factor (anti-VEGF) monotherapy with anti-VEGF therapy combined with sub-Tenon's capsule injections of triamcinolone acetonide (STTA) in patients with macular edema (ME) associated with branch retinal vein occlusion (BRVO). Retrospective observational study METHODS: This study included 186 eyes: 138 eyes received intravitreal injection of ranibizumab (IVR), and the remaining 48 eyes received IVR combined with STTA therapy. If additional IVR were necessary, STTA were performed simultaneously. Both groups showed a rapid reduction in ME. The changes in logMAR visual acuity (VA) from baseline to 12months were - 0.26 ± 0.26 in the IVR and - 0.20 ± 0.26 in the IVR with STTA groups (P = 0.209). The changes in mean central foveal thickness from baseline to 12months were - 226.9 ± 208.2µm in the IVR and - 236.0 ± 214.0µm in the IVR with STTA groups (P = 0.798). The required number of IVR was 3.4 ± 1.9 in the IVR group, and 3.4 ± 1.6 in the IVR and STTA group (P = 0.950). There were no significant differences in any parameters between the two groups. There were no clear differences between combination therapy of anti-VEGF with STTA and anti-VEGF monotherapy for the treatment of patients with ME associated with BRVO. The number of anti-VEGF injections in patients who received the combination therapy was not reduced as compared with the number of anti-VEGF injections in patients who received the monotherapy.

Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy

AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30%...

Effect of cataract surgery on macular thickness in diabetic patients

Purpose: To study the effect of cataract surgery on macular thickness in diabetic patients. Materials and Method: This prospective comparative study enrolled 100 diabetics and 100 non-diabetics undergoing cataract surgery fulfilling inclusion criteria. Complete ocular examination was done for both the groups preoperatively and postoperatively at 1 week, 1month and 3 months including central macular thickness evaluation using optical coherence tomography. Result: Significant increase in mean central foveal thickness in diabetics and in non-diabetics post 1 month (P

One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab.

To assess visual and optical coherence tomography-derived anatomical outcomes of treatment with intravitreal aflibercept (Eylea®) for diabetic macular oedema in patients switched from intravitreal ranibizumab (Lucentis®). Retrospective, cohort study. Ninety eyes (of 67 patients) receiving intravitreal anti-vascular endothelial growth factor therapy were included. This is a retrospective, real-life, cohort study. Each patient had visual acuity measurements and optical coherence tomography scans performed at baseline and 12 months after the first injection of aflibercept was given. We measured visual acuities in Early Treatment Diabetic Retinopathy Study letters, central foveal thickness and macular volume at baseline and at 12 months after the first aflibercept injection was given. Ninety switched eyes were included in this study. The mean (standard deviation) visual acuity was 63 (15.78) Early Treatment Diabetic Retinopathy Study letters. At baseline, the mean (standard deviation) central foveal thickness was 417.7 (158.4) μm and the mean macular volume was 9.96 (2.44) mm3. Mean change in visual acuity was +4 Early Treatment Diabetic Retinopathy Study letters (p = 0.0053). The mean change in macular volume was -1.53 mm3 in SW group (p = 0.21), while the change in central foveal thickness was -136.8 μm (p = 0.69). There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.

Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.

To assess structural and functional outcomes of treatment with intravitreal aflibercept (®Eylea) for diabetic macular oedema in treatment-naïve patients. Sixty-four eyes receiving intravitreal anti-vascular endothelial growth factor therapy were included in the data analysis of this retrospective, real-life study which follow-up was 3 years. Each patient had corrected visual acuity in Early Treatment Diabetic Retinopathy Study letters and optical coherence tomography central foveal thickness and macular volume performed at baseline, 12, 24 and 36 months. Patients were initiated on a loading phase of five 1-monthly intravitreal aflibercept injections, followed by injections if needed as per clinicians' discretion. The mean number of aflibercept injections received over 3 years was 12.59. At baseline, the mean visual acuity (standard deviation) (Snellen) was 61.45 (16.30) (20/63) Early Treatment Diabetic Retinopathy Study letters, the mean central foveal thickness (standard deviation) was 422 (138) µm, while the mean macular volume (standard deviation) was 9.51 (2.01) mm3. At 36 months, the mean visual acuity (standard deviation) (Snellen) was 68.34 (13.66) (20/50) Early Treatment Diabetic Retinopathy Study letters (p = .0003). Mean central foveal thickness (standard deviation) was 303 (106) µm (p < .0001) and mean macular volume (standard deviation) was 8.35 (1.62) mm3 (p = .0022) at 36 months. Sixteen (25%) eyes gained ≥15 ETDRS letters at month 36, and 33 (52%) eyes had a decrease in central foveal thickness of ≥ 100 µm at the same time. There was a significant improvement in visual acuity and in anatomical outcomes in aflibercept-treated eyes at 36 months after commencing treatment for diabetic macular oedema in real-life settings. The good vision and anatomical outcomes were maintained over second and third year of treatment with mean 2.93 and 2.57 intravitreal injections, respectively.

Foveal thickness, foveal microvasculature, and refractive error in children with asymmetric involvement of retinopathy of prematurity.

To evaluate foveal thickness, foveal microvasculature, and refractive error in children with asymmetric involvement of retinopathy of prematurity who had laser treatment in one eye and spontaneously regressed retinopathy of prematurity in the fellow eye. Totally, 17 children (34 eyes) with a history of asymmetric course of acute Zone II retinopathy of prematurity were assessed. Data on best-corrected visual acuity, refractive status, axial length, anterior chamber depth, and optical coherence tomography angiography findings were analyzed between treated and non-treated fellow eyes. Treated eyes were more myopic than non-treated eyes (mean, -0.09 ± 1.86 diopters vs mean, 0.07 ± 0.98 diopters, p = 0.026). Compared to non-treated eyes, treated eyes had shallower anterior chamber depth (mean, 3.27 ± 0.24mm vs mean, 3.55 ± 0.19mm, p = 0.02). No significant difference was observed regarding optical coherence tomography angiography parameters between two eyes of the children. The mean central foveal thickness was found to be higher in treated eyes than in non-treated eyes (297.46 ± 22.03 vs 275.55 ± 18.45, p = 0.009). Higher number of laser spots were associated with decreased parafoveal superficial capillary plexus vessel density (r = -0.56, p = 0.02) and increased central foveal thickness (r = 0.62, p = 0.008). Our results revealed no difference in optical coherence tomography angiography parameters between laser-treated and non-treated eyes in children with asymmetric involvement of Zone II retinopathy of prematurity except for a higher central foveal thickness in laser-treated eyes. Treated eyes were more myopic than the non-treated eyes. Number of laser applications during treatment had an impact on parafoveal superficial capillary plexus vessel density.